Clinical Trial: A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681271) titled 'A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)' on June 26.

Brief Summary: This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

Study Start Date: July 29

Study Type: INTERVENTIONAL

Condition: Papulopustular Rosacea

Intervention: DRUG: LOU064

LOU064 administered by oral route...